CPT code 91323 designates an mRNA-based COVID-19 vaccine product supplied for intramuscular administration at a dosage of 10 micrograms per 0.2 mL. This code captures the vaccine product itself and is integral to national vaccination efforts, facilitating standardized reporting, coverage determinations, and public health tracking. Its use matters for immunization programs, payer coverage policies, and provider billing workflows across ambulatory care settings.

Key payers included in discussions of CPT code 91323 are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national view of the code’s clinical context, common settings where the vaccine is administered, and the payer landscape relevant to coverage and claims processing. The publication provides benchmarks for utilization and reimbursement trends where available, notes on billing considerations, and summaries of recent policy updates affecting vaccine product coding and payment. Clinical context covers the mRNA platform and intramuscular route of administration, including dose specification. Data not available in the input is noted where applicable.